Verian Potential Name For Baxter Protein-Free Antihemophilic Factor VIII
This article was originally published in Pharmaceutical Approvals Monthly
Verian is a potential name for Baxter’s protein-free factor VIII product that is pending at FDA. The firm submitted the name to the Patent & Trademark Office for antihemophilic factor used for the treatment of hemophilia.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class